Congratulations to UCSF Bixby Center member Diana Greene Foster, PhD on receiving the Society of Family Planning's Robert A. Hatcher Family Planning Mentor Award.
Using data from a 2015 study on birth control access by Bixby researchers, the Brookings Institute and Child Trends produced a report estimating the impact and cost savings that would result from every woman having full access to the most effective contraceptive methods.
On March 2, the one-year anniversary of the Supreme Court hearing Whole Woman’s Health v. Hellerstedt, the Bixby Center and BIRCWH convened a symposium focused on science’s role in shaping policy.
Nearly half of pregnancies in the U.S. are unintended, and many result from people failing to use contraception correctly or consistently. One way to improve contraceptive use is to help women select contraceptive methods that better accommodate their personal preferences.
In a recent New England Journal of Medicine commentary, a group of experts including the Bixby Center’s Dr. Daniel Grossman called on the FDA to eliminate the FDA's excessive regulation of the medication abortion drug mifepristone.
A recent study co-authored by Daniel Grossman, MD interviewed administrators at publicly funded family planning organizations in Texas to identify barriers to offering vasectomy.
A group of experts, including Daniel Grossman, MD, director of ANSIRH and Bixby Center member, calls for an end to the FDA's overregulation of Mifeprex (mifepristone), a drug commonly used in medication abortions.
Prior to the 2014 Ebola outbreak, west African countries had made meaningful strides in reducing maternal mortality and improving access to care for mothers and children.
A new study, conducted by ANSIRH, finds that portrayals of abortion on TV make them seem much easier to get than they actually are, contributing to an overall lack of understanding about the realities of getting one.